Mauti Cancer Foundation’s Post

One day to go on our CrowdCube fundraise, now at just over £212,000 ... here is a short reminder of why #PeezyMidstream was invented by Dr Vincent Forte who was ahead of his time on accurate diagnoses, patient safety and infection control, with ongoing impact to prevention of AMR and Sepsis. Our focus on urine sample specifity has taken us into the world of early stage cancer detection, STI screening, sports dope testing and evidential forensic medicine - all areas where urine sample quality has been overlooked - until now, as @Forte Medical rolls up its sleeves and approaches these sectors with trademark ingenuity and determination. If you are in two minds about investing, ask any woman in your life who has suffered from UTI and/or prenatal urine screening about her experiences. You'll have your answer right there. Please join us on our journey and support this unique British SME with novel and much needed devices that are made in the UK with Boddingtons Limited. Please share! #medtech #femtech #womenshealth #cancer #diagnoses #sport #forensics #medicine #GP #pointofcare #primarycare #clinicalresearch #UTI #amr #sepsis #innovation #urinecollection #antimicrobialstewardship #antibiotics #invention #patientsafety #infectioncontrol #prenatal #antenatal #prevention Angel Investment Network Investing in Women Astia Angels Angel Academe - increasing female investment Ellevate Network Women of Wearables (wearables, health tech & femtech) Wellbeing of Women Women in Medicine Sepsis Alliance The UK Sepsis Trust Wellcome Trust The Francis Crick Institute The King's Fund The Patients Association Medicines Discovery Catapult Johnson & Johnson Medtronic BD https://lnkd.in/eMUydzHR

When we speak of supply chain resilience we also look to support and develop a future generation of innovative business thinkers and leaders to bring transformational products, processes and services into the marketplace.

A good story about an Included Health member's courageous journey to beat breast cancer. Guidance, advocacy, and quick access to high-quality healthcare is the digital front door for Health Plan members. https://lnkd.in/gPmMA6Re

ASCP BOC welcomes the Cytogenetics Examination Committee to a virtual meeting! Despite meeting virtually, the committee continues to work on the CG(ASCP) and CG(ASCP)i examinations. Shannon Gaskin, CG(ASCP)CM, the current Chair of the committee says, “We often have very interesting discussions about various exam-related topics, and it has been fun being involved in shaping the next exam that will be given to freshly minted technologists.” To learn more about joining this group of dedicated professionals in shaping the next cytogenetics exams, click on this link https://bit.ly/3umoQm8. #cytogenetics #volunteer #ASCPBOC #ASCPi

Raymond Mailhot, MD, MPH, and Erin Mobley, PhD, MPH, have been awarded a $741,000 grant from the Leukemia & Lymphoma Society to support their study, "Insurance Inequities in Hodgkin Lymphoma Treatment and Survivorship in the Southeast". Through interviews with cancer survivors and leveraging electronic medical records, they hope to identify how to bridge the disparities that under- and uninsured patients in the U.S. face and how they can recommend changes to public policy to improve outcomes for all patients. Read more in this press release: https://ufh.sc/4f0l0Bl #FloridaProtonResearch #CancerResearch #ResearchGrant #HodgkinLymphoma #Lymphoma #HodgkinLymphomaAwareness #survonc #cansurv #LymphomaAwareness #CancerCare

Think biG and be courageous! Will glioblastoma, “the hardest nut to crack”, prove amenable to combined neoantigen plus checkpoint inhibitor immunotherapy? It’s no secret that treating glioblastoma has proven to be one the most challenging tumors, among a list that also includes melanoma. For at least the last 26 years that I’m familiar with since my mom’s brief encounter, GBM patients have faced a futile and bleak prognosis with little change in the standard of care. But as we are beginning to appreciate, the Moderna-Merck Phase 2 clinical trial combining checkpoint inhibitor immunotherapy, Keytruda, with an mRNA neoantigen, personal cancer vaccine therapy strategy demonstrated remarkable promise in difficult to treat, high-risk melanoma patients. A bold new chapter in this developing story is being written in Australia using a similar strategy for GBM. Though still an “n=1 pilot program,” this moving, tag-team summary presentation offers a glimpse of marvel and hope for patients that today face the bleak reality of a terminal illness. https://lnkd.in/gpAAknCt

The future

Squats for Cancer! Follow the link below

DHCRC supports multiple projects in collaboration with Peter MacCallum Cancer Centre (Peter Mac) and we are proud of our partnership with Peter Mac in the fight against cancer.   ✨A medication adherence platform for reducing the cost of medication errors and non-adherence: The SAMSON app is designed to reduce incidents of medication errors and non-adherence by patients, supporting long-term management and adherence of medications.   ✨ CLOTS – technical solution: 4-model decision support tool for all surgical and interventional procedures: This project prevents the prevalence of thromboembolism (TE; clots) with a decision-support model that is personalised to practice.    ✨ A virtual clinical champion empowering optimal, equitable care for individuals living with genetic disorders: This project will develop and pilot a scalable, multidimensional platform (GenCare) to give individuals with genetic disorders access to specialist clinical genetics services.   ✨Implementation of a scalable platform to enable regulated digital health product development and commercialisation: This project enables data aggregation from various Peter Mac data ecosystems, presenting de-identified, curated, and multi-modal datasets for research and development of data.   #WorldCancerDay #Partnership #TogetherAgainstCancer #WorldCancerDay